September/October 2011

Approvals of potential blockbuster drugs represent a new source of revenue for pharmaceutical manufacturers, who will experience significant income loss from generic competition in 2011-2012.

Adherence to risperidone long-acting injection (RLAI) therapy in the outpatient setting was poor. Degree of discharge planning from inpatient hospitalization was not associated with RLAI adherence.

Compared with doxorubicin plus cyclophosphamide, docetaxel plus cyclophosphamide was highly cost-effective for adjuvant treatment of operable breast cancer.

This paper considers opportunities and barriers relating to medication taking and self-management by people with diabetes and related conditions as discussed during an invitational symposium.

Implementation of the STeP program across managed care organizations could lead to improved patient outcomes and significant cost savings.

Exploring how health plans and hemophilia treatment centers can better work together to deliver high-quality care and manage costs associated with hemophilia.

The potential OTC availability of Lipitor and other prescription drugs raises questions regarding value, safety, appropriateness, and insurance coverage.